Latest Biotech News

A wave of startups is positioning to exploit emerging FDA frameworks for bespoke, personalized gene‑editing therapies. One new CRISPR company is explicitly betting that regulators will ease...

The Biotechnology Innovation Organization launched the BIO Investment Council to improve capital formation for early‑stage biotech, pairing investors and emerging companies to tackle barriers to...

Aktis Oncology priced its IPO and raised $318 million, selling 17.65 million shares at $18 apiece. The Cambridge, Mass.-based radiopharmaceutical developer plans to use proceeds to advance its...

Eikon Therapeutics filed for a U.S. IPO, positioning the company as a potential bellwether for biotech public-market sentiment. The filing will be watched for demand signals around cutting-edge...

Krystal Biotech disclosed early clinical data indicating its gene therapy can deliver native protein to cystic fibrosis patients, and the company proposed advancing directly into a pivotal trial....

Phanes Therapeutics reported positive phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, in combination with chemotherapy for first‑line treatment of...

Orca Bio closed $250 million in financing to support the commercial launch of its T‑cell therapy for complications after allogeneic stem cell transplants. The capital will underwrite manufacturing...

City of Hope and Cellares signed an agreement to evaluate Cellares’ automated Cell Shuttle manufacturing and Cell Q QC platform for City of Hope’s CAR T program targeting glioblastoma. The...

Bionova Scientific entered a manufacturing alliance with Syenex to expand global access to plasmid DNA for genetic medicines and next‑generation delivery systems. Bionova will serve as Syenex’s...

Boltz launched as a public‑benefit corporation with $28 million in seed funding to democratize AI platforms for drug discovery and biomolecular design. Built by MIT CSAIL alumni and led by CEO...

Media reports say Merck is in talks to acquire Revolution Medicines in a potential $28–32 billion deal, a story that has fueled speculation about consolidation to refill oncology pipelines ahead...

Amgen agreed to acquire Dark Blue Therapeutics and its discovery platform for targeted degradation, including lead candidate DBT‑3757, in a transaction valued at $840 million. Dark Blue’s...

Aktis Oncology priced an upsized initial public offering and raised roughly $318 million, opening trading as one of the first biopharma IPOs of 2026. The company plans to fund phase 1b programs...

Eikon Therapeutics filed for an initial public offering, positioning itself as a bellwether for whether the biotech equity market can sustain a renewed IPO cadence. The filing reveals Eikon's...

Krystal Biotech disclosed early clinical proof‑of‑concept data for a mutation‑agnostic cystic fibrosis gene therapy and said it plans to move directly into a pivotal trial. The company reported...

A pivotal phase 3 trial reported that Lucerastat, an oral therapy, showed efficacy signals in patients with Fabry disease. The results detail clinical endpoints and safety observations that...

Phanes Therapeutics presented phase 2 data at ASCO‑GI showing spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, produced encouraging responses when added to chemotherapy in first‑line...

Boltz PBC, spun out of MIT CSAIL by developers of the Boltz series models, launched with a $28 million seed round led by Amplify, a16z and Zetta to commercialize open‑science AI platforms for...

A new wave of personalized gene‑editing ventures has emerged to exploit evolving regulatory pathways for bespoke therapies. Aurora Therapeutics, backed by Menlo Ventures and co‑founded by CRISPR...

Media reports indicate Merck is in talks to acquire Revolution Medicines for an offer in the $28–32 billion range, joining other potential bidders. Revolution’s late‑stage RAS pathway assets,...